

**Testimony of B. Braun's Chief  
Executive Officer, Carroll  
Neubauer, confirming that  
B. Braun did not agree with  
the EPA's classification of the  
dangerous ethylene oxide.**

**In the Matter Of:**

*CHRISTOPHER GLASS and EMILY GLASS vs*

*B. BRAUN MEDICAL, INC.*

---

*CAROLL NEUBAUER*

*February 01, 2022*

---



COURT OF COMMON PLEAS  
PHILADELPHIA COUNTY, PENNSYLVANIA

CHRISTOPHER GLASS and EMILY GLASS,

Plaintiffs,

Case No. 210500315

vs.

B. BRAUN MEDICAL, INC. et al.,

Defendants.

VIDEOTAPED DEPOSITION OF CAROLL NEUBAUER

HELD REMOTELY VIA ZOOM VIDEOCONFERENCE

February 1, 2022

10:11 a.m.

Reported By:  
Cheryll Kerr, CSR  
Job No. 2022-829321

COURT OF COMMON PLEAS  
PHILADELPHIA COUNTY, PENNSYLVANIA

CHRISTOPHER GLASS and EMILY GLASS,

Plaintiffs,

Case No. 210500315

vs.

B. BRAUN MEDICAL, INC. et al.,

Defendants.

VIDEOTAPED DEPOSITION OF CAROLL NEUBAUER, held  
remotely via Zoom Videoconference, before Cheryll Kerr,  
CSR, a Certified Shorthand Reporter and a Notary Public,  
on February 1, 2022, at 10:11 a.m.

1 APPEARANCES:

2 COUNSEL FOR PLAINTIFFS:

3 KLINE & SPECTER, PC  
4 BY: THOMAS BOSWORTH, ESQ.  
BY: AARON DUNBAR, ESQ.  
1525 Locust Street  
5 Philadelphia, PA 19102  
Phone: (215) 772-1000  
6 Email: Thomas.Bosworth@klinespecter.com  
Email: Aaron.Dunbar@klinespecter.com  
7

8 COUNSEL FOR GERMAN DEFENDANTS:

9 GREENBERG TRAUIG, LLP  
10 BY: LORI G. COHEN, ESQ.  
Terminus 200  
3333 Piedmont Road NE, Suite 2500  
11 Atlanta, GA 30305  
Phone: (678) 553-2385  
12 Email: CohenL@gtlaw.com

13 COUNSEL FOR U.S. DEFENDANTS:

14 HOGAN LOVELLS, LLP  
15 BY: JENNIFER ADAMS, ESQ.  
BY: CRISTINA RODRIGUEZ, ESQ.  
16 BY: ALEXANDER BOWERMAN, ESQ.  
609 Main Street, Suite 4200  
17 Houston, TX 77002  
Phone: (713) 632-1427  
18 Email: Jennifer.Adams@hoganlovells.com

19 Also Present:

20 Jennifer Prioleau, Esq., in-house counsel for B. Braun  
21 Medical, Inc.; Scott Perleau, Videographer

22 \*\*\* \*\*

1 A. Yes.

2 Q. And what was their response?

3 MS. ADAMS: Objection to form.

4 THE WITNESS: At that time, there was no  
5 immediate response. It was an information  
6 point that I gave waiting for further  
7 investigation on our behalf.

8 BY MR. BOSWORTH:

9 Q. What do you mean "waiting for further  
10 information on our behalf"?

11 A. That would be evaluating the findings of the  
12 EPA.

13 Q. Did you do that?

14 A. We did.

15 Q. What -- and what --

16 Was that done at the board meeting?

17 A. That was done with general counsel, assistant  
18 general counsel, the toxicologist I talked about, and  
19 sometimes with and sometimes without Dr. Wes  
20 Cetnarowski.

21 Q. Okay, and after you performed those  
22 evaluations, did you then go back to the board members  
23 of B. Braun Melsungen AG to report your findings to  
24 them?

25 A. I did.

1 Q. Okay. When did you do that?

2 A. Sometime after that.

3 Q. What was their response at that point, the  
4 German board members?

5 A. The findings that we had I think made us have  
6 less concern with the regard to the EPA classification  
7 and increased our doubt on the flaws of this study.

8 Q. The flaws of what study?

9 A. The EPA study.

10 Q. Okay. Did you express your doubt as to the  
11 EPA's conclusion to the board members of B. Braun  
12 Melsungen AG?

13 A. I expressed the differing opinions and basis  
14 of our findings that came from my discussions with  
15 counsel and general counsel.

16 Q. What was the response from the board members  
17 of B. Braun Melsungen AG to you telling them that?

18 A. I can't recall at this time.

19 Q. Okay. Did they ask you to do anything  
20 further at that time with regard to ethylene oxide?

21 A. Related directly to the study?

22 Q. Related to ethylene oxide at all.

23 A. I do not recall.

24 Q. How many different board meetings at B. Braun  
25 Melsungen AG have you discussed the topic of ethylene